Researchers at UCLA developed AlloCAR70-NKT, an allogeneic CD70-directed CAR-NKT cell therapy designed for off-the-shelf use against metastatic renal cell carcinoma. This approach combines multi-modal targeting of tumor cells and tumor microenvironment reprogramming, showing promising efficacy and safety in preclinical models. The therapy could overcome limitations of current treatments such as delayed availability and toxicity, addressing a substantial unmet medical need in aggressive kidney cancers.